37. Generalised pustular psoriasis Clinical trials / Disease details
Clinical trials : 79 / Drugs : 57 - (DrugBank : 21) / Drug target genes : 20 - Drug target pathways : 102
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-142430 | 01/2/2014 | A Phase 3 Clinical Study of KHK4827 | An Extension Study of KHK4827 Subjects with Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma | Psoriasis | Intervention name : KHK4827 INN of the intervention : brodalumab Dosage And administration of the intervention : Subcutaneous administration Control intervention name : null | Kyowa Hakko Kirin Co., Ltd. | NULL | 18 | BOTH | 165 | Phase 3 | NULL | |||
| 2 | NCT02052609 (ClinicalTrials.gov) | February 2014 | 30/1/2014 | A Phase 3 Clinical Study of KHK 4827 | An Extension Study of KHK4827 in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma | Psoriasis Vulgaris;Psoriatic Arthritis;Pustular; Psoriasis, Palmaris Et Plantaris;Psoriatic Erythroderma | Drug: KHK4827 140mg SC;Drug: KHK4827 210mg SC | Kyowa Kirin Co., Ltd. | NULL | Completed | 18 Years | N/A | All | 155 | Phase 3 | Japan |
| 3 | JPRN-JapicCTI-132057 | 01/2/2013 | An open-label, non-controlled study of KHK4827 in subjects with psoriasis | A Long-Term Study of KHK4827 in Subjects with Pustular Psoriasis (Generalized) and Psoriatic Erythroderma | Psoriasis | Intervention name : KHK4827 INN of the intervention : brodalumab Dosage And administration of the intervention : Subcutaneous administration Control intervention name : null | Kyowa Hakko Kirin Co., Ltd. | NULL | 18 | BOTH | Phase 3 | NULL | ||||
| 4 | NCT01782937 (ClinicalTrials.gov) | February 2013 | 27/1/2013 | An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis | A Long-Term Study of KHK4827 in Subjects With Pustular Psoriasis (Generalized) and Psoriatic Erythroderma | Psoriasis | Drug: KHK4827 | Kyowa Hakko Kirin Company, Limited | NULL | Completed | 18 Years | N/A | Both | 30 | Phase 3 | Japan |